Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Breccia

Showing results (1-10 of 427) with videos related to

Pageof 43
Sort By:
Hematology. American Society of Hematology. Education Program|December 9, 2023
Atypical CML: diagnosis and treatmentMassimo Breccia
Cardiovascular & Hematological Disorders Drug Targets|March 12, 2009
Resistance to imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problemMassimo Breccia, Giuliana Alimena
Current Drug Targets|June 13, 2009
Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABLMassimo Breccia, Giuliana Alimena
Expert Review of Hematology|November 29, 2014
Firstline treatment for chronic phase chronic myeloid leukemia patients should be based on a holistic approachMassimo Breccia, Giuliana Alimena
Expert Review of Molecular Diagnostics|April 3, 2025
Extracellular vesicles as source of biomarkers in hematological malignancies: looking towards clinical applicationsClaudia Ielo, Massimo Breccia
British Journal of Haematology|August 4, 2023
Interferon in chronic myeloid leukaemia: Is it useful for treatment-free remission?Massimo Breccia, Giuseppe Saglio
Cancer Letters|June 12, 2012
Suboptimal response in chronic myeloid leukemia patients treated with imatinib: early identification and new therapeutic challengesMassimo Breccia, Giuliana Alimena
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 3, 2011
Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patientsMassimo Breccia, Giuliana Alimena
Leukemia Research|September 29, 2009
Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemiaMassimo Breccia, Giuliana Alimena
Leukemia Research|March 25, 2009
The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolismMassimo Breccia, Giuliana Alimena
Pageof 43

Showing results (1-10 of 427) with videos related to

Sort By:
Pageof 43
Hematology. American Society of Hematology. Education Program|December 9, 2023
Atypical CML: diagnosis and treatmentMassimo Breccia
Cardiovascular & Hematological Disorders Drug Targets|March 12, 2009
Resistance to imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problemMassimo Breccia, Giuliana Alimena
Current Drug Targets|June 13, 2009
Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABLMassimo Breccia, Giuliana Alimena
Expert Review of Hematology|November 29, 2014
Firstline treatment for chronic phase chronic myeloid leukemia patients should be based on a holistic approachMassimo Breccia, Giuliana Alimena
Expert Review of Molecular Diagnostics|April 3, 2025
Extracellular vesicles as source of biomarkers in hematological malignancies: looking towards clinical applicationsClaudia Ielo, Massimo Breccia
British Journal of Haematology|August 4, 2023
Interferon in chronic myeloid leukaemia: Is it useful for treatment-free remission?Massimo Breccia, Giuseppe Saglio
Cancer Letters|June 12, 2012
Suboptimal response in chronic myeloid leukemia patients treated with imatinib: early identification and new therapeutic challengesMassimo Breccia, Giuliana Alimena
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 3, 2011
Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patientsMassimo Breccia, Giuliana Alimena
Leukemia Research|September 29, 2009
Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemiaMassimo Breccia, Giuliana Alimena
Leukemia Research|March 25, 2009
The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolismMassimo Breccia, Giuliana Alimena
Pageof 43